Nabriva Therapeutics is developing a new class of antibiotics; the pleuromutilins. These unique antimicrobial compounds interfere with bacterial protein synthesis via a specific interaction with the 23S rRNA of the 50S bacterial ribosome subunit. These compounds have a distinct anti-bacterial profile and show no cross-resistance with other classes of antibiotics. Nabriva’s world class medicinal chemistry expertise achieved, for the very first time, the development of intravenous and orally available pleuromutilins clearing the way for intravenous to oral step-down therapy. This achievement constitutes a very significant milestone in providing appropriate medication for the treatment of life-threatening bacterial infections.

Nabriva’s lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria. Extensive Phase I data have demonstrated that BC-3781 can achieve therapeutically relevant blood and tissue levels in man with excellent tolerability when administered by either oral or intravenous routes. Recent Phase II data show that BC-3781 has efficacy comparable to the gold standard, Vancomycin, and that it has a good safety profile in patients treated for serious skin infections. Based on these results, Nabriva has now successfully achieved proof-of-concept for the systemic use of pleuromutilin antibiotics in man to treat ABSSSI, community-acquired bacterial pneumonia (CABP) and other indications.

The company also has a Phase I topical pleuromutilin product candidate, BC-7013.